The effects of dapagliflozin on anemia of chronic kidney disease (Study A)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041200107

Enrollment

Registered

2021-03-08

Start date

2021-04-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease stage 3-4 and anemia of chronic kidney disease Dapagliflozin, diabetes mellitus, chronic kidney disease Anemia of chronic kidney disease, heart failure with reduced ejection fraction

Interventions

dapagliflozin

Dapagliflozin, SGLT2 inhibitor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Those with CKD stage 3-4 and diabetes mellitus or heart failure with reduced ejection fraction, those with CKD without diabetes or heart failure with reduced ejection fration (eGFR 15-59 mL/min/1.73m2) (2) Those on erythropoiesis stimulating agents (ESA) or hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors (3) Those without iron deficiency (transferrin saturation >= 20% or ferritin >= 50 ng/mL) (4) Those who are not on SGLT2 inhibitors (5) Those who gave informed consent (6) Age >= 20 years old at the time of consent (both men and women, and inpatients and outpatients) (7) For those with heart failure with reduced ejection fraction, they should be on standard therapy for heart failure (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics, or beta blockers)

Exclusion criteria

Exclusion criteria: (1) Those with history of allergy to dapagliflozin (2) Those with severe ketoacidosis, hyperosmolar coma or precoma, or type 1 diabetes (3) Those with hospitalization due to infection, surgery under general anesthesia, trauma requiring surgical intervention, gastrointestinal bleeding, transfusion, active malignancy within 3 months, or those expecting surgery within 3 months (4) Those with non-adherence (5) Pregnant or potentially pregnant women (6) Those whom treating physicians judge inappropriate candidates for participating in the study

Design outcomes

Primary

Measure	Time frame
The change in dose of ESA/HIF-PH inhibitors	—

Secondary

Measure	Time frame
Hemoglobin, erythropoietin, P, Mg, creatinine, blood pressure, body weight, blood sugar, HbA1c or glucoalbumin, ferittin, transferrin saturation, hepcidin, erythroferrone	—

Contacts

Public ContactKodai Suzuki

Nagoya City University Hospital

kodais@med.nagoya-cu.ac.jp+81-52-858-7429

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026